Suppr超能文献

腺病毒六邻体中外源肽掺入位点的鉴定。

Identification of sites in adenovirus hexon for foreign peptide incorporation.

作者信息

Wu Hongju, Han Tie, Belousova Natalya, Krasnykh Victor, Kashentseva Elena, Dmitriev Igor, Kataram Manjula, Mahasreshti Parameshwar J, Curiel David T

机构信息

Division of Human Gene Therapy, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.

出版信息

J Virol. 2005 Mar;79(6):3382-90. doi: 10.1128/JVI.79.6.3382-3390.2005.

Abstract

Adenovirus type 5 (Ad5) is one of the most promising vectors for gene therapy applications. Genetic engineering of Ad5 capsid proteins has been employed to redirect vector tropism, to enhance infectivity, or to circumvent preexisting host immunity. As the most abundant capsid protein, hexon modification is particularly attractive. However, genetic modification of hexon often results in failure of rescuing viable viruses. Since hypervariable regions (HVRs) are nonconserved among hexons of different serotypes, we investigated whether the HVRs could be used for genetic modification of hexon by incorporating oligonucleotides encoding six histidine residues (His6) into different HVRs in the Ad5 genome. The modified viruses were successfully rescued, and the yields of viral production were similar to that of unmodified Ad5. A thermostability assay suggested the modified viruses were stable. The His6 epitopes were expressed in all modified hexon proteins as assessed by Western blotting assay, although the intensity of the reactive bands varied. In addition, we examined the binding activity of anti-His tag antibody to the intact virions with the enzyme-linked immunosorbent assay and found the His6 epitopes incorporated in HVR2 and HVR5 could bind to anti-His tag antibody. This suggested the His6 epitopes in HVR2 and HVR5 were exposed on virion surfaces. Finally, we examined the infectivities of the modified Ad vectors. The His6 epitopes did not affect the native infectivity of Ad5 vectors. In addition, the His6 epitopes did not appear to mediate His6-dependent viral infection, as assessed in two His6 artificial receptor systems. Our study provided valuable information for studies involving hexon modification.

摘要

5型腺病毒(Ad5)是基因治疗应用中最有前景的载体之一。对Ad5衣壳蛋白进行基因工程改造已被用于改变载体嗜性、增强感染性或规避宿主预先存在的免疫反应。作为最丰富的衣壳蛋白,六邻体修饰尤其具有吸引力。然而,六邻体的基因修饰常常导致无法拯救出有活力的病毒。由于高变区(HVRs)在不同血清型的六邻体中不保守,我们研究了是否可以通过将编码六个组氨酸残基(His6)的寡核苷酸掺入Ad5基因组的不同HVRs中来对六邻体进行基因修饰。修饰后的病毒成功拯救出来,病毒产量与未修饰的Ad5相似。热稳定性分析表明修饰后的病毒是稳定的。通过蛋白质免疫印迹分析评估,所有修饰后的六邻体蛋白中均表达了His6表位,尽管反应条带的强度有所不同。此外,我们通过酶联免疫吸附测定法检测了抗His标签抗体与完整病毒粒子的结合活性,发现掺入HVR2和HVR5中的His6表位可以与抗His标签抗体结合。这表明HVR2和HVR5中的His6表位暴露在病毒粒子表面。最后,我们检测了修饰后的Ad载体的感染性。His6表位不影响Ad5载体的天然感染性。此外,在两个His6人工受体系统中评估发现,His6表位似乎不介导His6依赖性病毒感染。我们的研究为涉及六邻体修饰的研究提供了有价值的信息。

相似文献

1
Identification of sites in adenovirus hexon for foreign peptide incorporation.
J Virol. 2005 Mar;79(6):3382-90. doi: 10.1128/JVI.79.6.3382-3390.2005.
4
Genetic strategy to decrease complement activation with adenoviral therapies.
PLoS One. 2019 Apr 26;14(4):e0215226. doi: 10.1371/journal.pone.0215226. eCollection 2019.
5
Chimeric hexon HVRs protein reflects partial function of adenovirus.
Biochem Biophys Res Commun. 2012 May 4;421(2):170-6. doi: 10.1016/j.bbrc.2012.03.125. Epub 2012 Apr 3.
9
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Nature. 2006 May 11;441(7090):239-43. doi: 10.1038/nature04721. Epub 2006 Apr 16.
10
Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
J Virol. 2013 Sep;87(17):9661-71. doi: 10.1128/JVI.00462-13. Epub 2013 Jul 3.

引用本文的文献

1
Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice.
Int J Nanomedicine. 2025 Aug 6;20:9771-9785. doi: 10.2147/IJN.S511173. eCollection 2025.
2
Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?
Hum Gene Ther. 2022 Nov;33(21-22):1109-1120. doi: 10.1089/hum.2022.178. Epub 2022 Nov 4.
3
Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2.
Mol Ther. 2022 Dec 7;30(12):3639-3657. doi: 10.1016/j.ymthe.2022.08.002. Epub 2022 Aug 10.
5
Genetic strategy to decrease complement activation with adenoviral therapies.
PLoS One. 2019 Apr 26;14(4):e0215226. doi: 10.1371/journal.pone.0215226. eCollection 2019.
6
Progress in Adenoviral Capsid-Display Vaccines.
Biomedicines. 2018 Jul 26;6(3):81. doi: 10.3390/biomedicines6030081.
7
Retargeted and detargeted adenovirus for gene delivery to the muscle.
Virology. 2018 Jan 15;514:118-123. doi: 10.1016/j.virol.2017.10.005. Epub 2017 Nov 22.
9
Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line.
Pathol Oncol Res. 2017 Oct;23(4):829-835. doi: 10.1007/s12253-016-0160-8. Epub 2017 Jan 18.
10
Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease.
Pathog Immun. 2016 Fall-Winter;1(2):214-233. doi: 10.20411/pai.v1i2.114.

本文引用的文献

1
Fluorescently labeled adenovirus with pIX-EGFP for vector detection.
Mol Imaging. 2004 Apr;3(2):105-16. doi: 10.1162/15353500200404100.
4
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
J Virol. 2002 Dec;76(24):12775-82. doi: 10.1128/jvi.76.24.12775-12782.2002.
9
Targeted adenoviral vectors.
Biochim Biophys Acta. 2002 May 3;1575(1-3):1-14. doi: 10.1016/s0167-4781(02)00249-x.
10
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.
J Virol. 2002 May;76(9):4580-90. doi: 10.1128/jvi.76.9.4580-4590.2002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验